A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Status:
Withdrawn
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and
Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer
drug. CDX-1401 is a tumor specific antigen and Poly-ICL is a Toll-like receptor agonist tumor
specific antigens which when combined with Pembrolizumab may increase the tumor response to
this drug.